Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients

Journal of Viral Hepatitis

Volumn 12, Issue 1, 2005, Pages 67-73

  Westland, C E ^a   Yang, H ^a   Delaney IV, W E ^a   Wulfsohn, M ^a   Lama, N ^a   Gibbs, C S ^a   Miller, M D ^a   Fry, J ^a   Brosgart, C L ^a   Schiff, E R ^b   Xiong, Shelly ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Adefovir; Hepatitis B virus; Lamivudine; Liver; Mutation; Resistance; Transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTIC ACID; DNA POLYMERASE; FAMCICLOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; TYROSINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DNA HYBRIDIZATION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN MOTIF; PROTHROMBIN TIME; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION;

ADENINE; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHOSPHONIC ACIDS; PROTHROMBIN TIME; SERUM ALBUMIN; VIRAL LOAD;

EID: 19944430573     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00578.x     Document Type: Article

References (35)

1. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-1853.
2. Leung NWY, Lai CL, Dienstag J et al. Long-term safety of lamivudine in patients with chronic hepatitis B. In: A Lok, J Heathcote, J Liang, J Serrano, J Hoofnagle (eds). Management of Hepatitis B: 2000. Bethesda, MD: National Institutes of Health, 2000, 92.
3. Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180.
4. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
5. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/ hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896.
6. Perrillo R, Rakela J, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581-1586.
7. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-633.
8. Ono SK, Kato N, Shiratori Y et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107: 449-455.
9. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716.
10. Wolters LM, Niesters HG, Hansen BE et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol 2002; 24: 173-181.
11. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723.
12. Leung NW, Lai CL, Guan R, Liaw YF. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001; 34: 348A (Abstract 706).
13. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107-113.
14. Yoshida EM, Ma MM, Davis JE et al. Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up. Can J Gastroenterol 1998; 12: 125-129.
15. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir nonresponse, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998; 29: 669-675.
16. Bock T, Tillman HL, Torresi J et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264-273.
17. Tillmann HL, Bock TC, Locarnini SA et al. Risk factors for selection of YMDD mutants, their consequences in liver transplant recipients, ranging from sudden onset of liver failure to no disease. Hepatology 2000; 32: 376A.
18. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-1677.
19. Cooley L, Ayres A, Bartholomeusz A et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17(11): 1649-1657.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote J et al. Adefovir dipivoxil for the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
21. Marcellin P, Chang TT, Lim SG et al. Aefovir dipivoxil for the treatment of HBeAg positive chronic hepatitis B: a double-blind, randomized, placebo-controlled trial. N Engl J Med 2003; 348: 800-808.
22. Schiff ER, Lai C-L, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38: 1419-1427.
23. Yang H, Westland CE, Delaney WE IV et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36: 464-473.
24. Cane PA, Mutimer D, Ratcliffe D et al. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir Ther 1999; 4: 7-14.
25. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
26. Gutfreund KS, Williams M. George R et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000; 33: 469-475.
27. Xiong X, Yang H, Westland CE, Zou R, Gibbs CS. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 2000; 31: 219-224.
28. Seigneres B, Aguesse-Germon S, Pichoud C et al. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol 2001; 34: 114-122.
29. Delaney WE IV, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841.
30. Tang S, Ho S, Moniri K, Lai K, Chan T. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002; 73: 148-151.
31. Wolters LM, Honkoop P, Niesters HG, de Man RA. Efficacy of famciclovir treatment in chronic hepatitis B patients with different mutations at position 552 of the DNA polymerase gene. J Hepatol 1998; 28: 909-910.
32. Pichoud C, Seignères B, Wang Z, Trépo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29: 230-237.
33. Delaney WE, Edwards R, Colledge D et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45: 1705-1713.
34. Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, Zoulim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181: 1221-1233.
35. Delaney WE IV, Yang H, Miller MD, Gibbs CS, Xiong S. Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro. J Hepatol 2002; 36: 89.